Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group has received marketing authorization in China for its ustekinumab biosimilar injection Enyike, a fully human monoclonal antibody targeting IL-12 and IL-23 for the treatment of plaque psoriasis, including paediatric patients, and Crohn’s disease. Developed as a Class 3.3 therapeutic biological product, Enyike demonstrated high similarity in quality, pharmacokinetics, efficacy and safety to originator drug Stelara in head-to-head trials, and its approval significantly enhances CSPC’s autoimmune disease portfolio while offering Chinese patients a new, locally developed treatment option in a major biologics segment.
The company followed established biosimilar development guidelines and published its comparative clinical results in the Journal of the American Academy of Dermatology, underscoring the scientific rigor behind Enyike’s development. This regulatory milestone is expected to bolster CSPC’s position in the competitive autoimmune biologics market in China, potentially improving access and affordability for patients who have failed or are intolerant to conventional systemic therapies and phototherapies.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-incorporated pharmaceutical company focused on developing and manufacturing innovative and generic drugs, including biologics, for the Chinese market. The group has been expanding its presence in high-value therapeutic areas such as autoimmune diseases, aiming to broaden its product portfolio and strengthen its competitive position in specialty medicines.
Average Trading Volume: 86,073,692
Technical Sentiment Signal: Hold
Current Market Cap: HK$85.01B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.